The high expression of TC1 (C8orf4) was correlated with the expression of β-catenin and cyclin D1 and the progression of squamous cell carcinomas of the tongue

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 7061-7067

  Zhang, Peng ^a,b   Cao, Hong Yi ^a   Bai, Lin Lin ^a   Li, Wei Nan ^a   Wang, Yuan ^a   Chen, Song Yan ^a   Zhang, Li ^a   Yang, Lian He ^a   Xu, Hong Tao ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b The 463 Hospital of Chinese PLA   (China)

Author keywords

C8orf4; Chibby; Cyclin D1; Oral cancer; Thyroid cancer 1; Catenin

Indexed keywords

BETA CATENIN; CYCLIN D1; PEPTIDES AND PROTEINS; PROTEIN CHIBBY; PROTEIN TC1; UNCLASSIFIED DRUG; C8ORF4 PROTEIN, HUMAN; CARRIER PROTEIN; CBY1 PROTEIN, HUMAN; NUCLEAR PROTEIN; TUMOR PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TONGUE CARCINOMA; TUMOR DIFFERENTIATION; WNT SIGNALING PATHWAY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CYCLIN D1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; TONGUE NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84947056307     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3423-1     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. de Souza MV, Servato JP, Loyola AM, Cardoso SV, Chammas R, Liu FT, et al. Expression of APC protein during tongue malignant transformation in galectin-3-deficient mice challenged by the carcinogen 4-nitroquniline-n-oxide. Int J Clin Exp Pathol. 2014;7(6):3255–63.
3. Henriques AC, de Matos FR, Galvao HC, Freitas RA. Immunohistochemical expression of MMP-9 and VEGF in squamous cell carcinoma of the tongue. J Oral Sci. 2012;54(1):105–11.
4. Sahu N, Grandis JR. New advances in molecular approaches to head and neck squamous cell carcinoma. Anticancer Drugs. 2011;22(7):656–64.
5. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007;26(3-4):645–62.
6. Sunde M, McGrath KC, Young L, Matthews JM, Chua EL, Mackay JP, et al. TC-1 is a novel tumorigenic and natively disordered protein associated with thyroid cancer. Cancer Res. 2004;64(8):2766–73.
7. Chua EL, Young L, Wu WM, Turtle JR, Dong Q. Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics. 2000;69(3):342–7.
8. Wang YD, Bian GH, Lv XY, Zheng R, Sun H, Zhang Z, et al. TC1 (C8orf4) is involved in ERK1/2 pathway-regulated G(1)- to S-phase transition. BMB Rep. 2008;41(10):733–8.
9. Friedman JB, Brunschwig EB, Platzer P, Wilson K, Markowitz SD. C8orf4 is a transforming growth factor B induced transcript downregulated in metastatic colon cancer. Int J Cancer. 2004;111(1):72–5.
10. Jung Y, Bang S, Choi K, Kim E, Kim Y, Kim J, et al. TC1 (C8orf4) enhances the Wnt/beta-catenin pathway by relieving antagonistic activity of Chibby. Cancer Res. 2006;66(2):723–8.
11. Kim B, Koo H, Yang S, Bang S, Jung Y, Kim Y, et al. TC1(C8orf4) correlates with Wnt/beta-catenin target genes and aggressive biological behavior in gastric cancer. Clin Cancer Res. 2006;12(11 Pt 1):3541–8.
12. Kim J, Kim Y, Kim HT, Kim DW, Ha Y, Kim CH, et al. TC1(C8orf4) is a novel endothelial inflammatory regulator enhancing NF-kappaB activity. J Immunol. 2009;183(6):3996–4002.
13. Kim Y, Kim J, Park J, Bang S, Jung Y, Choe J, et al. TC1(C8orf4) is upregulated by IL-1beta/TNF-alpha and enhances proliferation of human follicular dendritic cells. FEBS Lett. 2006;580(14):3519–24.
14. Yang ZQ, Moffa AB, Haddad R, Streicher KL, Ethier SP. Transforming properties of TC-1 in human breast cancer: interaction with FGFR2 and beta-catenin signaling pathways. Int J Cancer. 2007;121(6):1265–73.
15. Su K, Huang L, Li W, Yan X, Li X, Zhang Z, et al. TC-1 (c8orf4) enhances aggressive biologic behavior in lung cancer through the Wnt/beta-catenin pathway. J Surg Res. 2014;185(1):255–63.
16. Xu HT, Liu Y, Liu SL, Miao Y, Li QC, Wang EH. TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas. Virchows Arch. 2013;462(3):281–7.
17. Jung Y, Kim M, Soh H, Lee S, Kim J, Park S, et al. TC1(C8orf4) regulates hematopoietic stem/progenitor cells and hematopoiesis. PLoS One. 2014;9(6), e100311.
18. Liu F, Millar SE. Wnt/beta-catenin signaling in oral tissue development and disease. J Dent Res. 2010;89(4):318–30.
19. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–17.
20. Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer. Cell Signal. 2014;26(3):570–9.
21. Xi Y, Chen Y. Wnt signaling pathway: Implications for therapy in lung cancer and bone metastasis. Cancer Lett. 2014;353(1):8–16.
22. Xie XM, Zhang ZY, Yang LH, Yang DL, Tang N, Zhao HY, et al. Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol. 2013;43(5):1636–42.
23. Xu HT, Xie XM, Li QC, Liu SL, Dai SD, Liu Y, et al. Atonal homolog 1 expression in lung cancer correlates with inhibitors of the Wnt pathway as well as the differentiation and primary tumor stage. APMIS. 2013;121(2):111–9.
24. Noguti J, DEM CF, Hossaka TA, Franco M, Oshima CT, Dedivitis RA, et al. The role of canonical WNT signaling pathway in oral carcinogenesis: a comprehensive review. Anticancer Res. 2012;32(3):873–8.
25. Gonzalez-Moles MA, Ruiz-Avila I, Gil-Montoya JA, Plaza-Campillo J, Scully C. Beta-catenin in oral cancer: an update on current knowledge. Oral Oncol. 2014;50(9):818–24.
26. Odajima T, Sasaki Y, Tanaka N, Kato-Mori Y, Asanuma H, Ikeda T, et al. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol. 2005;36(3):234–41.
27. Iwai S, Katagiri W, Kong C, Amekawa S, Nakazawa M, Yura Y. Mutations of the APC, beta-catenin, and axin 1 genes and cytoplasmic accumulation of beta-catenin in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131(12):773–82.
28. Fischer V, Brown-Grant DA, Li FQ. Chibby suppresses growth of human SW480 colon adenocarcinoma cells through inhibition of β-catenin signaling. J Mol Signal. 2012;7(1):6.
29. Xu HT, Li QC, Dai SD, Xie XM, Liu DI, Wang EH. The expression patterns and correlations of chibby, beta-catenin, and DNA methyltransferase-1 and their clinicopathological significance in lung cancers. APMIS. 2011;119(11):750–8.
30. Vandepoele K, Staes K, Andries V, van Roy F. Chibby interacts with NBPF1 and clusterin, two candidate tumor suppressors linked to neuroblastoma. Exp Cell Res. 2010;316(7):1225–33.